Compare FNWD & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | LUCD |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.6M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | FNWD | LUCD |
|---|---|---|
| Price | $38.78 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $34.00 | $3.94 |
| AVG Volume (30 Days) | 41.8K | ★ 709.8K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $66,563,999.00 | $4,399,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | $8.03 | $152.14 |
| P/E Ratio | $20.44 | ★ N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $26.12 | $0.75 |
| 52 Week High | $39.99 | $1.80 |
| Indicator | FNWD | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 61.67 |
| Support Level | $36.37 | $1.02 |
| Resistance Level | $39.99 | $1.16 |
| Average True Range (ATR) | 1.32 | 0.05 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 79.16 | 100.00 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.